Vol 24, No 2 (2017)
Letters to the Editor — Clinical cardiology
Published online: 2017-04-14

open access

Page views 1459
Article views/downloads 1480
Get Citation

Connect on Social Media

Connect on Social Media

Determinants of improvement in six-minute walk distance from admission to discharge in acute systolic heart failure: Analysis from the ESCAPE trial

Hesham R. Omar, Maya Guglin
Pubmed: 28421593
Cardiol J 2017;24(2):227-230.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Fleg JL, Pina IL, Balady GJ, et al. Assessment of Functional Capacity in Clinical and Research Applications : An Advisory From the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation. 2000; 102(13): 1591–1597.
  2. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1): 111–117.
  3. Passantino A, Lagioia R, Mastropasqua F, et al. Short-term change in distance walked in 6 min is an indicator of outcome in patients with chronic heart failure in clinical practice. J Am Coll Cardiol. 2006; 48(1): 99–105.
  4. Abraham WT, Fisher WG, Smith AL, et al. MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002; 346(24): 1845–1853.
  5. Binanay C, Califf RM, Hasselblad V, et al. ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005; 294(13): 1625–1633.
  6. Shah MR, Hasselblad V, Stinnett SS, et al. Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes. J Card Fail. 2001; 7(2): 105–113.
  7. Gualeni A, D'Aloia A, Gentilini A, et al. Effects of maximally tolerated oral therapy on the six-minute walking test in patients with chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1998; 81(11): 1370–1372.
  8. Hutcheon SD, Gillespie ND, Crombie IK, et al. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial. Heart. 2002; 88(4): 373–377.
  9. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995; 92(6): 1499–1506.
  10. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation. 1996; 94(11): 2793–2799.